FDA Requests Market Withdrawal of Belviq Due to Cancer Risk

FRIDAY, Feb. 14, 2020 -- A clinical trial of the weight-loss drug Belviq (lorcaserin) shows an association with an increased risk for cancer, and the U.S. Food and Drug Administration is requesting that its maker withdraw the drug from the U.S....
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news